Multiple causes of cardiotoxic effects in patients with chronic myeloid leukemia - Reply

Jonathan Douxfils; Hélène Haguet; Jean Michel Dogné

doi:10.1001/jamaoncol.2016.1011

Multiple causes of cardiotoxic effects in patients with chronic myeloid leukemia - Reply

Jonathan Douxfils, Hélène Haguet, Jean Michel Dogné

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	829
Number of pages	1
Journal	JAMA oncology
Volume	2
Issue number	6
DOIs	https://doi.org/10.1001/jamaoncol.2016.1011
Publication status	Published - 1 Jun 2016

Access to Document

10.1001/jamaoncol.2016.1011

Cite this

@article{894a5f09f02a4d108e83ae52dc558487,

title = "Multiple causes of cardiotoxic effects in patients with chronic myeloid leukemia - Reply",

author = "Jonathan Douxfils and H{\'e}l{\`e}ne Haguet and Dogn{\'e}, {Jean Michel}",

year = "2016",

month = jun,

day = "1",

doi = "10.1001/jamaoncol.2016.1011",

language = "English",

volume = "2",

pages = "829",

journal = "JAMA oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Multiple causes of cardiotoxic effects in patients with chronic myeloid leukemia - Reply

AU - Douxfils, Jonathan

AU - Haguet, Hélène

AU - Dogné, Jean Michel

PY - 2016/6/1

Y1 - 2016/6/1

UR - http://www.scopus.com/inward/record.url?scp=85010635839&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2016.1011

DO - 10.1001/jamaoncol.2016.1011

M3 - Letter

C2 - 27281625

SN - 2374-2437

VL - 2

SP - 829

JO - JAMA oncology

JF - JAMA oncology

IS - 6

ER -

Multiple causes of cardiotoxic effects in patients with chronic myeloid leukemia - Reply

Access to Document

Other files and links

The DIT project : Drug induced thrombosis - a special focus on kinase and PARP inhibitors and

Cite this

Multiple causes of cardiotoxic effects in patients with chronic myeloid leukemia - Reply

Access to Document

Other files and links

Projects

The DIT project : Drug induced thrombosis - a special focus on kinase and PARP inhibitors and

Cite this